Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259074 · ClinicalTrials.gov registry record · Phase 3
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
A Phase 3 study of Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 859
- Enrollment target
- 20
- Study locations
NCT03259074 is a Phase 3 study of Ankylosing Spondylitis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 859 participants, below the 38,140-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT03259074, a Phase 3 study of Ankylosing Spondylitis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 859 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing Spondylitis (AS).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL GP2017 (adalimumab biosimilar)
- BIOLOGICAL AIN457 150 mg
Study Locations (20)
California
- Novartis Investigative Site - Escondido
- Novartis Investigative Site - La Mesa
- Novartis Investigative Site - San Francisco
Ohio
- Novartis Investigative Site - Dayton
- Novartis Investigative Site - Middleburg Heights
Arizona
- Novartis Investigative Site - Mesa
Florida
- Novartis Investigative Site - Gainesville
Idaho
- Novartis Investigative Site - Boise
Louisiana
- Novartis Investigative Site - Shreveport
Maryland
- Novartis Investigative Site - Wheaton
Montana
- Novartis Investigative Site - Great Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 859 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2021-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259074
The ClinicalTrials.gov registry entry for NCT03259074 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 859 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38,140-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (98% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ankylosing Spondylitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03259074 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT03259074 about?
NCT03259074 is a clinical study titled "Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)". The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing Spondylitis (AS).
What is the current status of trial NCT03259074?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 859 participants. The study started on 2017-11-30. Estimated completion is 2021-11-29.
What conditions does trial NCT03259074 study?
This clinical trial studies the following conditions: Ankylosing Spondylitis.
What interventions are being tested in trial NCT03259074?
The interventions under investigation include: Placebo (BIOLOGICAL), GP2017 (adalimumab biosimilar) (BIOLOGICAL), AIN457 150 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT03259074?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03259074 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ankylosing Spondylitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
ACTIVE NOT RECRUITING · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.